New Lyme Disease Guidelines Welcomed by Sufferers of Chronic Lyme Disease
Current treatments for Lyme disease, particularly chronic forms of the disease, are inadequate, according to a new treatment guideline written by a group of leading experts.
Adopted by the International Lyme and Associated Disease Society (ILADS) and published in the Expert Review of Anti-infective Therapy, the guideline also proposes revamped treatment guidelines to help clinicians across the globe deliver better care to patients.
Lyme disease is a bacterial infection caused by infected ticks, and is thought to affect 300,000 people annually in the US alone. The chronic form of the disease, which sees long-lasting symptoms including fatigue, headaches and joint pain, is regularly misdiagnosed and mismanaged by clinicians.
The paper claims that current antibiotic protocols used by many physicians to prevent and treat Lyme disease are ineffective, and can actually lead to an increased risk of Lyme disease developing into a chronic illness.
Daniel Cameron MD, lead author of the study said: “We are seeing more people diagnosed with Lyme disease who simply don’t get better after being treated. Our goal with these new guidelines is to provide evidence-based, patient-centred care for sufferers, helping clinicians make the right treatment decisions.
“We strongly recommend that patient goals and values regarding treatment options be identified and considered during a shared decision-making process.”
The paper also notes the desperate need for better understanding of this complex illness. Currently there is limited available evidence regarding treatment.
Cameron continued: “The lack of pharmaceutical interest in Lyme disease and its concomitant funding has led to therapeutic innovation coming from clinicians. But we unquestionably need more research to better define the disease process and to establish highly effective therapeutic regimens.”
View the full journal article here.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance